When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BPMC - Blueprint Medicines: GIST Setback Unlikely To Deter Future
Blueprint Medicines Corporation
Blueprint suffers GIST setbacks
NDA changes
Blueprint Medicines (BPMC) recently announced the FDA will split Avapritinib New Drug Application into separate submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST, setting the company back a quarter. In order to prioritize these submissions, Blueprint is also delaying their COMPASS-2L trial in second-line GIST.
The delays punished shares of BPMC to the degree of 15%:
As a result, main competitor, Deciphera (DCPH), jumped:
My take
Recall: Blueprint's data in both 4th-line GIST and PDGFRA Exon 18 Mutant GIST is extremely strong and